PD+ Health: How and when to engage with Industry - setting up for success

In this seminar Elane Zelcer will cover tips on how and when to engage with industry, and explain the benefits of building better bridges with industry. Elane will also cover the relevant funding sources, organisations and initiatives that encourage industry enabling upskilling of students and researchers for the broader marketplace, and how positive engagement may bring about new sources of revenue streams and create a way to support your innovations to come to market.

• Why engage with industry?
• The benefits of engaging with industry
• An overview of the current landscape and future directions in industry engagement
• Tips and strategies on engaging with industry
• Sourcing funding to assist with engagement

Meet your presenter:

Elane is a leader in the healthtech (biotech, medtech, digital health) sector. She has more than 25 years’ experience as an advisor to start-up and early stage companies, university & MRI spin-outs and research teams, with guidance for capital raising and commercialisation including risk management and governance. Her career spans director, scientific advisory board, executive management, management consulting, start-up founder and research roles, almost exclusively focused on healthtech. Elane is Deputy Chair of BioMelbourne Network, Director with AllergyPal, Director of her own company, BioConsult and a member of the scientific advisory board of AUSiMED (Australia Israel Medical Research).

Her focus is the intersection between business and the research sector where she uses her knowledge and skills to assist start-up/early stage companies and research based organisations to develop novel, value-add healthtech products. Elane’s BSc (Hons), PhD & Grad Dip Mktg are from Monash University, and she completed post-doctoral studies at McMaster University, Hamilton, Ontario, Canada and the University of Virginia, Charlottesville, Virginia, USA. In 2017 she was awarded the Distinguished Alumni Award by Monash’s Faculty of Science, and is a Fellow of the Australian Institute of Company Directors.